Oncolytic viruses as therapeutic agents

References

• De Page N G. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia 1912; 9: 82–8
   Google Scholar
• Webb H E. Viruses in the treatment of cancer. Lancet 1970; 1: 1206–8
   PubMed Web of Science ®Google Scholar
• Smith R R, Huebner R J, Rowe W P, Schatten W E, Thomas L B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211–8
   PubMed Web of Science ®Google Scholar
• Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34: 1907–28
   PubMed Web of Science ®Google Scholar
• Gross S. Measles and leukaemia. Lancet 1971; 1: 397–8
   PubMed Web of Science ®Google Scholar
• Taylor M W, Cordell B, Souhrada M, Prather S. Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc Natl Acad Sci USA 1971; 68: 836–40
   PubMed Web of Science ®Google Scholar
• Reichard K W, Lorence R M, Cascino C J, Peeples M E, Walter R J, Fernando M B, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448–53
   PubMed Web of Science ®Google Scholar
• Cassell W, Garrett R E. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863
   PubMed Web of Science ®Google Scholar
• Lorence R M, Rood P A, Kelley K W. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 1988; 80: 1305–12
   PubMed Web of Science ®Google Scholar
• Cassel W A, Murray D R, Phillips H S. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856–60
   PubMed Web of Science ®Google Scholar
• Southam C M, Moore A E. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer 1952; 5: 1025–34
   PubMed Web of Science ®Google Scholar
• Coen D M, Kosz-Vnenchak M, Jacobson J G, Leib D A, Bogard C L, Schaffer P A, et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 1989; 86: 4736–40
   PubMed Web of Science ®Google Scholar
• Markert J M, Malick A, Coen D M, Martuza R L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597–603
   PubMed Web of Science ®Google Scholar
• Martuza R L, Malick A, Markert J M, Ruffner K L, Coen D M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854–6
   PubMed Web of Science ®Google Scholar
• Southam C M, Moore A E. West Nile, Ilhéus and Bunyamwera virus infection in man. J. Trop Med 1951; 31: 724–41
   Web of Science ®Google Scholar
• Bischoff J R, Kim D H, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–6
   PubMed Web of Science ®Google Scholar
• Freytag S O, Rogulski K R, Paielli D L, Gilbert J D, Kim J H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323–33
   PubMed Web of Science ®Google Scholar
• Wildner O, Blaese R M, Morris J C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV-tk. Cancer Res 1999; 59: 410–3
   PubMed Web of Science ®Google Scholar
• Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A, et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res 1999; 59: 3411–6
   PubMed Web of Science ®Google Scholar
• Wildner O, Morris J C. The role of the E1B 55 kDa gene in oncolytic adenoviral vectors expressing HSV-tk: assessment of anti-tumor efficacy and toxicity. Cancer Res 2000; 60: 4167–74
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, Lee P S, McDonnell T J, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2–12
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur E R, Lim H Y, Henderson G A, Simons J W, Henderson D R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–63
   PubMed Web of Science ®Google Scholar
• Yu D C, Chen Y, Seng M, Dilley J, Henderson D R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200–3
   PubMed Web of Science ®Google Scholar
• Hallenbeck P L, Chang Y N, Hay C, Golightly D, Stewart D, Lin J, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721–33
   PubMed Web of Science ®Google Scholar
• Sauthoff H, Heitner S, Rom W N, Hay J G. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379–88
   PubMed Web of Science ®Google Scholar
• Rancourt C, Piche A, Gomez-Navarro J, Wang M, Alvarez R D, Siegal G P, et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin Cancer Res 1999; 5: 43–50
   PubMed Web of Science ®Google Scholar
• Goldstein D J, Weller S K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196–205
   PubMed Web of Science ®Google Scholar
• Randazzo B P, Kucharczuk J C, Litzky L A, Kaiser L R, Brown S M, Maclean A, et al. Herpes simplex 1716—an ICP 34.5 mutant—is severely replication restricted in human skin xenografts in vivo. Virology 1996; 223: 392–5
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin S D, Yazaki T, Hunter W D, Martuza R L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–43
   PubMed Web of Science ®Google Scholar
• Coffey M C, Strong J E, Forsyth P A, Lee P W. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–4
   PubMed Web of Science ®Google Scholar
• Rommelaere J, Cornelis J J. Antineoplastic activity of parvo-viruses. J Virol Methods 1991; 33: 233–51
   PubMed Web of Science ®Google Scholar
• Cassel W A, Garrett R E. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18: 863–8
   PubMed Web of Science ®Google Scholar
• Csatary L K, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619–27
   PubMedGoogle Scholar
• Mastrangelo M J, Eisenlohr L C, Gomella L, Lattime E C. Poxvirus vectors: orphaned and underappreciated. J Clin Invest 2000; 105: 1031–4
   PubMed Web of Science ®Google Scholar
• Gromeier M, Lachmann S, Rosenfeld M R, Gutin P H, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000; 97: 6803–8
   PubMed Web of Science ®Google Scholar
• Stojdl D F, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821–5
   PubMed Web of Science ®Google Scholar
• Shenk T. Adenoviridea. Fields' Virology, B N Fields, D M Knipe, P M Howley. Lippincott-Raven, Philadelphia, PA 1996; 2111–48
   Google Scholar
• Bergelson J M, Cunningham J A, Droguett G, Kurt-Jones E A, Krithivas A, Hong J S, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–3
   PubMed Web of Science ®Google Scholar
• Tiainen M, Pajalunga D, Ferrantelli F, Soddu S, Salvatori G, Sacchi A, et al. Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation. Cell Growth Differ 1996; 7: 1039–50
   PubMedGoogle Scholar
• Yew P R, Berk A J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357: 82–5
   PubMed Web of Science ®Google Scholar
• Yew P R, Kao C C, Berk A J. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis. Virology 1990; 179: 795–805
   PubMed Web of Science ®Google Scholar
• Barker D D, Berk A J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–21
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D D, Kim D H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–45
   PubMed Web of Science ®Google Scholar
• Hall A R, Dix B R, O'Carroll S J, Braithwaite A W. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068–72
   PubMed Web of Science ®Google Scholar
• Rothmann T, Hengstermann A, Whitaker N J, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470–8
   PubMed Web of Science ®Google Scholar
• Goodrum F D, Ornelles D A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479–90
   PubMed Web of Science ®Google Scholar
• Goldsmith K T, Dion L D, Curiel D T, Garver R I. J. trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. Virology 1998; 248: 406–19
   PubMed Web of Science ®Google Scholar
• Turnell A S, Grand R J, Gallimore P H. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73: 2074–83
   PubMed Web of Science ®Google Scholar
• Harada J N, Berk A J. p53-Independent and dependent requirements for ElB-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333–44
   PubMed Web of Science ®Google Scholar
• Hay J G, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom W N. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral Elb-55kD gene. Hum Gene Ther 1999; 10: 579–90
   PubMed Web of Science ®Google Scholar
• Vollmer C M, Ribas A, Butterfield L H, Dissette V B, Andrews K J, Eilber F C, et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999; 59: 4369–74
   PubMed Web of Science ®Google Scholar
• Morris J C, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56–62
   PubMed Web of Science ®Google Scholar
• Wildner O, Morris J C. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med 2000; 2: 353–60
   PubMed Web of Science ®Google Scholar
• Goodrum F D, Ornelles D A. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol 1997; 71: 548–61
   PubMed Web of Science ®Google Scholar
• Babiss L E, Ginsberg H S. Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis. J virol 1984; 50: 202–12
   PubMed Web of Science ®Google Scholar
• Bridge E, Ketner G. Interaction of adenoviral E4 and E1b products in late gene expression. Virology 1990; 174: 345–53
   PubMed Web of Science ®Google Scholar
• Halbert D N, Cutt J R, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250–7
   PubMed Web of Science ®Google Scholar
• Leppard K N, Shenk T. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism. EMBO J 1989; 8: 2329–36
   PubMed Web of Science ®Google Scholar
• Pilder S, Moore M, Logan J, Shenk T. The adenovirus ElB-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol 1986; 6: 470–6
   PubMed Web of Science ®Google Scholar
• Harrison T, Graham F, Williams J. Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 1977; 77: 319–29
   PubMed Web of Science ®Google Scholar
• Ho Y S, Galos R, Williams J. Isolation of type 5 adenovirus mutants with a cold-sensitive host range phenotype: genetic evidence of an adenovirus transformation maintenance function. Virology 1982; 122: 109–24
   PubMed Web of Science ®Google Scholar
• Khuri F R, Nemunaitis J, Ganly I, Arseneau J, Tannock I F, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nut Med 2000; 6: 879–85
   PubMed Web of Science ®Google Scholar
• Gu D L, Gonzalez A M, Printz M A, Doukas J, Ying W, D'Andrea M, et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999; 59: 2608–14
   PubMed Web of Science ®Google Scholar
• Doukas J, Hoganson D K, Ong M, Ying W, Lacey D L, Baird A, et al. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J 1999; 13: 1459–66
   PubMed Web of Science ®Google Scholar
• Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–81
   PubMed Web of Science ®Google Scholar
• Ilsley D D, Lee S H, Miller W H, Kuchta R D. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504–10
   PubMed Web of Science ®Google Scholar
• Thust R, Schacke M, Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res 1996; 31: 105–13
   PubMed Web of Science ®Google Scholar
• Haynes P, Lambert T R, Mitchell I D. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat Res 1996; 369: 65–74
   PubMed Web of Science ®Google Scholar
• Freeman S M, Abboud C N, Whartenby K A, Packman C H, Koeplin D S, Moolten F L, et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–83
   PubMed Web of Science ®Google Scholar
• Culver K W, Ram Z, Wallbridge S, Ishii H, Oldfield E H, Blaese R M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–2
   PubMed Web of Science ®Google Scholar
• Wildner O, Moms J C, Vahanian N N, Ford H J, Ramsey W J, Blaese R M. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57–62
   PubMed Web of Science ®Google Scholar
• Wildner O, Morris J C. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: dissemination, persistence, shedding, and pathogenicity. Hum Gene Ther, in press
   Web of Science ®Google Scholar
• Alemany R, Lai S, Lou Y C, Jan H Y, Fang X, Zhang W W. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999; 6: 21–5
   PubMed Web of Science ®Google Scholar
• Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996; 93: 11307–12
   PubMed Web of Science ®Google Scholar
• Chou J, Kern E R, Whitley R J, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262–6
   PubMed Web of Science ®Google Scholar
• Whitley R J, Kimberlin D W, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26: 541–53
   PubMed Web of Science ®Google Scholar
• Jia W W, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F. Selective destruction of gliomas in immuno-competent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994; 86: 1209–15
   PubMedGoogle Scholar
• Nilaver G, Muldoon L L, Kroll R A, Pagel M A, Breakefield X O, Davidson B L, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci U S A 1995; 92: 9829–33
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin S D, Martuza R L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963–6
   PubMed Web of Science ®Google Scholar
• Mineta T, Rabkin S D, Yazaki T, Hunter W D, Martuza R L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–43
   PubMed Web of Science ®Google Scholar
• Boviatsis E J, Chase M, Wei M X, Tamiya T, Hurford R KJ, Kowall N W, et al. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 1994; 5: 183–91
   PubMed Web of Science ®Google Scholar
• Poon A P, Roizman B. Differentiation of the shutoff of protein synthesis by virion host shutoff and mutant gamma (1)34.5 genes of herpes simplex virus 1. Virology 1997; 229: 98–105
   PubMed Web of Science ®Google Scholar
• MacLean A R, ul-Fareed M, Robertson L, Harland J, Brown S M. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence. J Gen Virol 1991; 72: 631–9
   PubMed Web of Science ®Google Scholar
• Taha M Y, Brown S M, Clements G B, Graham D I. The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice. J Gen Virol 1990; 71: 1597–601
   PubMed Web of Science ®Google Scholar
• Valyi-Nagy T, Fareed M U, O'Keefe J S, Gesser R M, MacLean A R, Brown S M, et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75: 2059–63
   PubMed Web of Science ®Google Scholar
• Brown S M, MacLean A R, Aitken J D, Harland J. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J Gen Virol 1994; 75: 3679–86
   PubMed Web of Science ®Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859–66
   PubMed Web of Science ®Google Scholar
• Markert J M, Medlock M D, Rabkin S D, Gillespie G Y, Todo T, Hunter W D, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867–74
   PubMed Web of Science ®Google Scholar
• Pyles R B, Warnick R E, Chalk C L, Szanti B E, Parysek L M. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8: 533–44
   PubMed Web of Science ®Google Scholar
• Boursnell M E, Entwisle C, Ali S A, Sivasubramaniam S D, Reeder S, McLean C S, et al. Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Adv Exp Med Biol 1998; 451: 379–84
   PubMed Web of Science ®Google Scholar
• Dilloo D, Rill D, Entwistle C, Boursnell M, Zhong W, Holden W, et al. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 1997; 89: 119–27
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin S D, Martuza R L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177–85
   PubMed Web of Science ®Google Scholar
• Walker J R, McGeagh K G, Sundaresan P, Jorgensen T J, Rabkin S D, Martuza R L. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10: 2237–43
   PubMed Web of Science ®Google Scholar
• Kooby D A, Carew J F, Halterman M W, Mack J E, Bertino J R, Blumgart L H, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13: 1325–34
   PubMed Web of Science ®Google Scholar
• Coukos G, Makrigiannakis A, Montas S, Kaiser L R, Toyozumi T, Benjamin I, et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7: 275–83
   PubMed Web of Science ®Google Scholar
• Chahlavi A, Todo T, Martuza R L, Rabkin S D. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162–9
   PubMedGoogle Scholar
• Randazzo B P, Bhat M G, Kesari S, Fraser N W, Brown S M. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997; 108: 933–7
   PubMed Web of Science ®Google Scholar
• Todo T, Rabkin S D, Chahlavi A, Martuza R L. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999; 10: 2869–78
   PubMed Web of Science ®Google Scholar
• Miyatake S, Martuza R L, Rabkin S D. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222–8
   PubMed Web of Science ®Google Scholar
• Aghi M, Chou T C, Suling K, Breakefield X O, Chiocca E A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovirherpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861–5
   PubMed Web of Science ®Google Scholar
• Sabin A B. Reoviruses: a new group of respiratory and enteric viruses formerly calssified as ECHO type 10 is described. Science 1959; 130: 1387–9
   PubMed Web of Science ®Google Scholar
• Tyler K L, Fields B N. Reoviruses and their replication. Fields' Virology, B N Fields, D M Knipe, P M Howley. Lippincott-Raven, Philadelphia, PA 1996; 1597–623
   Google Scholar
• Jackson G G, Muldoon R L. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J Infect Dis 1973; 128: 811–66
   PubMed Web of Science ®Google Scholar
• Duncan M R, Stanish S M, Cox D C. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444–9
   PubMed Web of Science ®Google Scholar
• Hashiro G, Loh P C, Yau J T. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307–15
   PubMed Web of Science ®Google Scholar
• Strong J E, Coffey M C, Tang D, Sabinin P, Lee P W. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351–62
   PubMed Web of Science ®Google Scholar
• Clarke P, Meintzer S M, Gibson S, Widmann C, Garrington T P, Johnson G L, et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000; 74: 8135–9
   PubMed Web of Science ®Google Scholar
• Bos J L. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9, [published erratum appears in Cancer Res 1990 50 1352]
   PubMed Web of Science ®Google Scholar
• Berns K I. Parvoviridae: The viruses and their replication. Fields' Virology, B N Fields, D M Knipe, P M Howley. Lippincott-Raven, Philadelphia 1996; 2173–97
   Google Scholar
• Dupressoir T, Vanacker J M, Cornelis J J, Duponchel N, Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989; 49: 3203–8
   PubMed Web of Science ®Google Scholar
• Dupont F, Avalosse B, Karim A, Mine N, Bosseler M, Maron A, et al. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther 2000; 7: 790–6
   PubMed Web of Science ®Google Scholar
• Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989–95
   PubMed Web of Science ®Google Scholar
• Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72: 3018–28
   PubMed Web of Science ®Google Scholar
• Rayet B, Lopez-Guerrero J A, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signaling pathway. J Virol 1998; 72: 8893–903
   PubMed Web of Science ®Google Scholar
• Rommelaere J, Cornelis J J. Antineoplastic activity of parvo-viruses. J Virol Methods 1991; 33: 233–51
   PubMed Web of Science ®Google Scholar
• Perros M, Deleu L, Vanacker J M, Kherrouche Z, Spruyt N, Faisst S, et al. Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells. J Virol 1995; 69: 5506–15
   PubMed Web of Science ®Google Scholar
• Fuks F, Deleu L, Dinsart C, Rommelaere J, Faisst S. ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. J Virol 1996; 70: 1331–9
   PubMed Web of Science ®Google Scholar
• Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992; 35: 325–30
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Ahlert T, Probstle T, Steiner H H, Herold-Mende C, Gerhards R, et al. Immunization with virus-modified tumor cells. Semin Oncol 1998; 25: 677–96
   PubMed Web of Science ®Google Scholar
• Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in inter-generic poliovirus recombinants. Proc Natl Acad Sci USA 1996; 93: 2370–5
   PubMed Web of Science ®Google Scholar
• Jang S K, Krausslich H G, Nicklin M J, Duke G M, Palmenberg A C, Wimmer E. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol 1988; 62: 2636–43
   PubMed Web of Science ®Google Scholar
• Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988; 334: 320–5
   PubMed Web of Science ®Google Scholar
• Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999; 73: 958–64
   PubMed Web of Science ®Google Scholar
• Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93: 11341–8
   PubMed Web of Science ®Google Scholar
• Mastrangelo M J, Maguire H C, Lattime E C. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000; 465: 391–400
   PubMed Web of Science ®Google Scholar
• Overwijk W W, Lee D S, Surman D R, Irvine K R, Touloukian C E, Chan C C, et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999; 96: 2982–7
   PubMed Web of Science ®Google Scholar
• Zajac P, Schutz A, Oertli D, Noppen C, Schaefer C, Heberer M, et al. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res 1998; 58: 4567–71
   PubMed Web of Science ®Google Scholar
• Mastrangelo M J, Maguire H C, Eisenlohr L C, Laughlin C E, Monken C E, McCue P A, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409–22
   PubMed Web of Science ®Google Scholar
• Kloke O, Niederle N. Development and mechanisms of interferon resistance. Cancer Treat Rev 1990; 17(Suppl A)81–8
   PubMed Web of Science ®Google Scholar
• Rose J K, Schubert M. Rhabdovirus genomes and their products. The rhabdoviruses, R R Wagner. Plenum, New York 1987; 129–66
   Google Scholar
• Banks T A, Rouse B T. Herpesviruses-immune escape artists?. Clin Infect Dis 1992; 14: 933–41
   PubMed Web of Science ®Google Scholar
• Mullbacher A. Viral escape from immune recognition: multiple strategies of adenoviruses. Immunol Cell Biol 1992; 70: 59–63
   PubMed Web of Science ®Google Scholar
• Bramson J L, Hitt M, Gauldie J, Graham F L. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997; 4: 1069–76
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm C M, Aboody-Guterman K S, Silver J S, Ikeda K, Johnston K M, et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-I vector. Gene Ther 1998; 5: 809–19
   PubMed Web of Science ®Google Scholar
• Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector- mediated tumor therapy in immunocompetent mice. Gene Ther 1999; 6: 1751–8
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin S D, Kojima H, Martuza R L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385–93
   PubMed Web of Science ®Google Scholar
• Todo T, Rabkin S D, Sundaresan P, Wu A, Meehan K R, Herscowitz H B, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10: 2741–55
   PubMed Web of Science ®Google Scholar
• Shisler J, Duerksen-Hughes P, Hermiston T M, Wold W S, Gooding L R. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J Virol 1996; 70: 68–77
   PubMed Web of Science ®Google Scholar
• Roth J A, Cristiano R J. Gene therapy for cancer: what have we done and where are we going?. J Natl Cancer Inst 1997; 89: 21–39
   PubMed Web of Science ®Google Scholar
• Jain R K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50(3 Suppl)814s–9s
   PubMed Web of Science ®Google Scholar
• Carroll N M, Chase M, Chiocca E A, Tanabe K K. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res 1997; 69: 413–7
   PubMed Web of Science ®Google Scholar
• Todo T, Rabkin S D, Martuza R L. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 2000; 7: 939–46
   PubMed Web of Science ®Google Scholar
• Chase M, Chung R Y, Chiocca E A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclo-phosphamide chemotherapy. Nat Biotechnol 1998; 16: 444–8
   PubMed Web of Science ®Google Scholar